Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Could aminoglutethimide replace adrenalectomy? This question has already been answered in clinical practice in the United Kingdom, for surgical adrenalectomy has declined markedly in frequency as new hormonal therapy has appeared. An optimal assessment of an endocrine therapy can only be made in previously untreated patients because of the heterogeneity of previously treated populations. Thus aminoglutethimide (AG) and adrenalectomy have been compared for previously untreated and treated populations. Because AG is commonly called 'medical adrenalectomy', this article will review and compare aminoglutethimide therapy with surgical adrenalectomy and make the case that surgical adrenalectomy is no longer indicated in the management of breast cancer.

Original publication

DOI

10.1007/BF01806770

Type

Journal article

Journal

Breast Cancer Res Treat

Publication Date

1985

Volume

6

Pages

201 - 211

Keywords

Adrenal Cortex, Adrenalectomy, Aminoglutethimide, Bone Neoplasms, Breast Neoplasms, Clinical Trials as Topic, Combined Modality Therapy, Estrogens, Female, Humans, Menopause, Neoplasms, Hormone-Dependent, Ovary, Steroids, Tamoxifen